Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease

Hughes, D., Gonzalez, D., Maegawa, G., Bernat, J. A., Holida, M., Giraldo, P., Atta, M. G., Chertkoff, R., Alon, S., Almon, E. B., Rocco, R., & Goker-Alpan, O. (2023). Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease. Genetics in Medicine, 25(12), 100968. https://doi.org/10.1016/j.gim.2023.100968
Authors:
Derralynn Hughes
Derlis Gonzalez
Gustavo Maegawa
John A. Bernat
Myrl Holida
Pilar Giraldo
Mohamed G. Atta
Raul Chertkoff
Sari Alon
Einat Brill Almon
Rossana Rocco
Ozlem Goker-Alpan
Affiliated Authors:
Gustavo Maegawa
Columbia Affiliation:
Subjects:
Fabry Disease (MeSH)
Author Keywords:
anti-drug antibodies
enzyme replacement therapy
estimated glomerular filtration rate
fabry disease
pegunigalsidase alfa
elink
Publication Type:
Article
Unique ID:
10.1016/j.gim.2023.100968
PMID:
37634127
DOI:
10.1016/j.gim.2023.100968
Journal:
Genetics in Medicine
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record
View PubMed Record

Record Created: